2022
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research 2022, 29: 174-182. PMID: 36074155, PMCID: PMC9811155, DOI: 10.1158/1078-0432.ccr-22-1138.Peer-Reviewed Original ResearchConceptsBreast cancer brain metastasesActive brain metastasesObjective response rateCNS objective response rateCancer brain metastasesBrain metastasesT-DXdPatient-derived xenograftsPDX modelsCohort studyTrastuzumab deruxtecanClinical efficacyClinical trialsHER2-positive breast cancer brain metastasesMetastatic HER2-positive breast cancerResponse rateMulti-institutional cohort studyHER2-positive breast cancerRetrospective multi-institutional cohort studyOrthotopic patient-derived xenograftsRetrospective cohort studyProspective clinical trialsSubset of patientsCentral nervous system activityPivotal clinical trials
2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosisAssociation of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2018, 36: jco.2017.76.003. PMID: 29298117, PMCID: PMC5815405, DOI: 10.1200/jco.2017.76.0033.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerTriple-negative breast cancerPrimary triple-negative breast cancerTumor fractionSomatic copy number alterationsCell-free DNABreast cancerSingle tertiary care institutionCopy number alterationsRetrospective cohort studySpecific somatic copy number alterationsTertiary care institutionNovel therapeutic approachesNumber alterationsCfDNA tumor fractionMetastatic survivalPrior chemotherapyTNBC cohortMetastatic settingCohort studyOverall survivalCancer Genome AtlasClinicopathologic factorsWorse survivalPrimary tumor
2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study
Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. The Breast 2016, 30: 136-140. PMID: 27721193, DOI: 10.1016/j.breast.2016.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMiddle AgedNeutropeniaPaclitaxelPractice Patterns, Physicians'Retrospective StudiesYoung AdultConceptsGranulocyte-colony stimulating factorDose-dense paclitaxelTreatment delayGroup 1High baseline absolute neutrophil countBaseline absolute neutrophil countSingle-institution retrospective studyDana-Farber Cancer InstituteStimulating factorRoutine G-CSFPercent of patientsRetrospective cohort studyAbsolute neutrophil countMajority of patientsAdverse eventsCohort studyNeutrophil countTreatment cessationProspective studyRetrospective studyT therapyBreast cancerGroup 2PatientsCancer Institute
2015
Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals Of Surgical Oncology 2015, 22: 4280-4286. PMID: 25893416, PMCID: PMC4801503, DOI: 10.1245/s10434-015-4570-8.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryInitial breast-conserving surgeryLocoregional recurrenceMargin statusLobular carcinomaBreast tumor recurrenceRetrospective cohort studyPositive surgical marginsInvasive lobular carcinomaMedian followInitial surgeryMultimodality therapyCohort studyFurther surgeryAdditional surgeryClinicopathologic dataSurgical marginsSurgical optionsNegative marginsTumor sizeCancer CenterClose marginsConsensus guidelinesTumor recurrence
2013
Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study. Clinical Breast Cancer 2013, 13: 254-263. PMID: 23829891, PMCID: PMC4084778, DOI: 10.1016/j.clbc.2013.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'PrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival RateTamoxifenYoung AdultConceptsTrastuzumab-based therapyFirst-line trastuzumab-based therapyAdvanced HER2-positive breast cancerHER2-positive breast cancerAdjuvant trastuzumabBreast cancerClinicopathological featuresClinical benefitC-statisticHuman epidermal growth factor-2-positive breast cancerTreatment durationPredictive valueHormone receptor-positive tumorsLong-term clinical benefitPrevious adjuvant trastuzumabTreatment duration groupsRetrospective cohort studyDisease-free intervalHormone receptor positivityReceptor-positive tumorsDuration of treatmentMagnitude of benefitLow predictive valueLogistic regression modelsDifferent logistic regression models
2005
The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries
Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries. Journal Of General Internal Medicine 2005, 20: 38-44. PMID: 15693926, PMCID: PMC1490029, DOI: 10.1111/j.1525-1497.2004.40079.x.Peer-Reviewed Original ResearchConceptsPrimary care physiciansCare physiciansBreast cancer diagnosisAdvanced cancerOutpatient careNumber of visitsMedical specialistsAdvanced stage diagnosisPreventive care visitsRetrospective cohort studyCancer diagnosisBreast cancer stagePercent of womenPopulation-based sampleCare visitsCohort studyCancer RegistryCancer stageUse of servicesElderly womenAdjusted ratesBreast cancerLower median incomeAmbulatory careHigh risk
2003
Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer.
Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. Journal Of Clinical Oncology 2003, 21: 4532-9. PMID: 14673040, DOI: 10.1200/jco.2003.05.131.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryDefinitive surgeryMedical oncologistsType of surgeryElderly womenAxillary dissectionBreast cancerEarly-stage breast cancerGuideline-recommended careRetrospective cohort studyAxillary node dissectionBreast cancer treatmentPercent of womenPopulation-based sampleComorbid illnessesNode dissectionCohort studyGuideline recommendationsDifferentiated cancerTeaching hospitalAdjusted proportionSurgeryOncologistsCancer treatmentWomen